• Email
  • Help

Information for you

On this page, we highlight information of partcular relevance for media, including news, events and featured information for journalists with a professional interest in the development and availability of medicines in the European Union.

For more information and details relevant for media, see our News & events section. 

For enquiries from media, please contact the EMA press office

Featured information

News for media

Events of interest

  • 16/03/2017 - 17/03/2017


    European Medicines Agency veterinary medicines info day

    The European Medicines Agency veterinary medicines info day, organised in collaboration with International Federation for Animal Health Europe (IFAH-Europe), provides first-hand information on the latest developments in the scientific review, regulation and marketing authorisation procedure in the field of veterinary medicine regulation. For the first time, this year, European Medicines Agency (EMA) will have dedicated information points on esubmissions, veterinary application submissions and veterinary medicines innovation. ... Read more

  • 19/05/2017

    First anniversary of PRIME: experience so far

    The European Medicines Agency (EMA) launched the PRIME (PRIority Medicines) scheme in March 2016. The scheme provides early and enhanced support to medicines that have the potential to address patients’ unmet needs. This meeting is organised by EMA to review the experience gained with PRIME one year after it was launched. The aim of the meeting is to receive feedback from users and potential users of the scheme, provide information on how the rules on eligibility have been applied and what types of support applicants have received so far and discuss practical examples that illustrate the benefits of PRIME and how it builds on the existing tools.  ... Read more

  • 28/03/2017


    Workshop on revising the guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicines

    The European Medicines Agency (EMA) held a public consultation a concept paper which outlined the major areas for revision of the ‘Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products’, from July to September 2016. Subsequently, EMA published a draft revised guideline for public consultation, from November 2016 to February 2017. This technical workshop aims to finalise the guidance with further involvement of stakeholders including from other regulatory agencies, pharmaceutical industry, contract research organisations and academia. The focus of the workshop will be on discussing comments received during the public consultations, therefore participation of external stakeholders is limited to those individuals and organisations who submitted comments. The output of the workshop will be reflected in the final revised guideline and the published overview of comments. ... Read more

  • 20/01/2017


    First 2017 meeting of the coordinating group of the European network of paediatric research at the European Medicines Agency (Enpr-EMA)

    The Enpr-EMA coordinating group contributes to the short and long-term strategy of the network, discusses and solves operational and scientific issues for the network, reports to the Paediatric Committee, which acts as the scientific committee of Enpr-EMA, and acts as a forum for communication. The group meets three times every year. ... Read more

  • 27/10/2017


    European Medicines Agency / Drug Information Association signal management information day

    This information day will provide an update on essential signal detection and management activities in the European Union (EU) for the overall surveillance and risk management of medicines. It will explore the final guidance provided following the finalisation of the good pharmacovigilance practices module IX on signal management and related aspects of the EU pharmacovigilance legislation. It will also cover marketing authorisation holders’ access to EudraVigilance and the resources and training the Agency provides to support stakeholders. Finally, it will discuss stakeholders’ approaches and perspectives on signal management. ... Read more

  • See all Events of interest

Information for:

Find information for...